Advertisement

PepGen Inc. PEPG

Set alert

Price alert · PEPG

All alert types
2.36 USD -0.05 -2.07%

At close · Oct 30

2.41 +0.05 +2.12%

After hours · Oct 30, 7:49 PM ET

Bid
2.34 × 2
Ask
2.35 × 2
2.22 Day range 2.41
1.35 52-week range 7.17
YTD
-63.75%
1 year
-47.90%
Open
2.40
Prev close
2.41
Mkt cap
163.24M
Vol
1.13M
Avg vol
938.28K
EPS
-1.01
P/E
0.00
Div yield
0.00%
More statistics
Low
2.22
High
2.41
Forward P/E
-1.45
Beta
1.76
Short ratio
5.75
Inst. own
96.36%
Dividend
0.00
Ex-div date
Earnings
Aug 8, 2024
50-d avg
6.03
200-d avg
11.24
1y target
15.40

MAX chart

Chart tools
Interval

Events in this range
  • Mar 6, 2024Earnings: —; estimate -1.01; surprise —%
  • May 14, 2024Earnings: -0.63; estimate -0.74; surprise 14.86%
  • May 14, 2024Earnings: —; estimate -0.74; surprise —%
  • May 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Jul 31, 2024Rating: Wedbush · Outperform → Outperform
  • Aug 1, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Aug 8, 2024Earnings: —; estimate -0.72; surprise —%
  • Aug 8, 2024Earnings: -0.87; estimate -0.72; surprise -20.83%
  • Nov 7, 2024Earnings: -0.66; estimate -0.87; surprise 24.14%
  • Nov 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Nov 8, 2024Rating: Wedbush · Outperform → Outperform
  • Nov 18, 2024Rating: B of A Securities · Neutral → Neutral
Signals (65)
NameDateAgo
SMA: BullishOct 5, 20263 weeks ago
SMA: BearishSep 28, 20261 month ago
SMA: BearishSep 21, 20261 month ago
SMA: BullishAug 17, 20262 months ago
SMA: BullishAug 3, 20262 months ago
SMA: BearishJul 27, 20263 months ago
MACD: Buy SignalJul 6, 20263 months ago
SMA: BullishJun 15, 20264 months ago
SMA: BearishMar 16, 20267 months ago
SMA: BearishMar 2, 20268 months ago
SMA: BullishFeb 9, 20268 months ago
MACD: Sell SignalJan 19, 20269 months ago
SMA: BearishJan 12, 20269 months ago
RSI: OverboughtDec 29, 202510 months ago
RSI: OverboughtNov 17, 202511 months ago
RSI: OverboughtSep 22, 20251 year ago
SMA: BullishSep 15, 20251 year ago
SMA: BullishSep 1, 20251 year ago
SMA: BearishAug 25, 20251 year ago
SMA: BullishAug 18, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BullishJul 21, 20251 year ago
SMA: BearishJun 9, 20251 year ago
SMA: BearishMar 17, 20251 year ago
SMA: BullishFeb 24, 20251 year ago
MACD: Buy SignalFeb 24, 20251 year ago
RSI: OversoldJan 13, 20251 year ago
RSI: OversoldNov 11, 20241 year ago
SMA: BearishOct 7, 20242 years ago
SMA: BullishSep 30, 20242 years ago
SMA: BearishJul 29, 20242 years ago
SMA: BearishJul 29, 20242 years ago
MACD: Sell SignalJul 29, 20242 years ago
MACD: Buy SignalMay 27, 20242 years ago
SMA: BullishMay 20, 20242 years ago
SMA: BearishMay 13, 20242 years ago
SMA: BullishApr 29, 20242 years ago
MACD: Sell SignalApr 15, 20242 years ago
SMA: BearishApr 1, 20242 years ago
RSI: OverboughtFeb 5, 20242 years ago
SMA: BullishDec 25, 20232 years ago
SMA: BullishNov 27, 20232 years ago
MACD: Buy SignalOct 16, 20233 years ago
SMA: BearishJun 5, 20233 years ago
SMA: BearishJun 5, 20233 years ago
MACD: Sell SignalJun 5, 20233 years ago
MACD: Buy SignalMay 29, 20233 years ago
SMA: BullishMay 22, 20233 years ago
SMA: BearishMay 15, 20233 years ago
SMA: BullishApr 24, 20233 years ago
SMA: BullishApr 24, 20233 years ago
SMA: BearishMar 27, 20233 years ago
SMA: BearishMar 20, 20233 years ago
MACD: Sell SignalMar 20, 20233 years ago
SMA: BullishMar 13, 20233 years ago
MACD: Buy SignalMar 13, 20233 years ago
MACD: Sell SignalMar 6, 20233 years ago
SMA: BearishFeb 27, 20233 years ago
SMA: BullishJan 2, 20233 years ago
SMA: BearishDec 26, 20223 years ago
SMA: BullishOct 3, 20224 years ago
RSI: OversoldSep 12, 20224 years ago
SMA: BearishAug 8, 20224 years ago
SMA: BullishJul 18, 20224 years ago
SMA: BearishJul 11, 20224 years ago

Key statistics

Market cap
126.80M
Enterprise value
-1.49M
Trailing P/E
0.00
Forward P/E
-1.45
PEG ratio
0.00
Price / sales
0.00
Price / book
0.92
EPS (TTM)
-2.98
Beta
1.76
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-52.01M
Total cash
138.86M
Total debt
19.04M
Return on equity
-66.26%
Shares outstanding
32.60M
Short % of float
4.52%
50-day average
6.03
200-day average
11.24

Analyst view

Consensus: buy

Buy
Price target (mean) 15.40 +552.5% upside
Target (low)
6.00
Target (mean)
15.40
Target (high)
26.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Aug 8, 2024

Expected Aug 8, 2024. Consensus EPS estimate -0.72.

Earnings history

Financials — quick view

All financials
PEPG Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PEPG Net income — quarterly -17.81M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PEPG EPS — quarterly -0.26
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

PEPG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.87-0.66+0.21+24.14%
Aug 8, 2024Jun 1, 2024-0.72———
Aug 8, 2024Jun 1, 2024-0.72-0.87-0.15-20.83%
May 14, 2024Mar 1, 2024-0.74-0.63+0.11+14.86%
May 14, 2024Mar 1, 2024-0.74———
Mar 6, 2024Dec 1, 2023-1.01———

Upgrades / downgrades

PEPG analyst upgrades and downgrades
DateFirmActionFromTo
Nov 18, 2024B of A SecuritiesmainNeutralNeutral
Nov 8, 2024WedbushmainOutperformOutperform
Nov 8, 2024HC Wainwright & Co.reitBuyBuy
Aug 1, 2024HC Wainwright & Co.reitBuyBuy
Jul 31, 2024WedbushreitOutperformOutperform
May 15, 2024HC Wainwright & Co.reitBuyBuy

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
pepgen.com

News

Your note

Sign in to keep a note on PEPG — it syncs with the Stock Master app.

Insider holders

PEPG insider holders
InsiderRelationLatest transactionDateShares held
GOYAL JAYAOfficerSaleMar 23, 20230
MCARTHUR JAMES G PH.D.Chief Executive OfficerPurchaseNov 29, 20231,694
MELLION MICHELLE LOfficerSaleJul 24, 20240
RA CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseFeb 8, 20240
SVENSTRUP NIELSOfficerSaleMay 16, 20240

Institution ownership

PEPG institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.32.79%10,689,54541.58MSep 29, 2024
Janus Henderson Group PLC7.17%2,336,5169.09MSep 29, 2024
Suvretta Capital Management, LLC5.10%1,660,9326.46MSep 29, 2024
Viking Global Investors, L.P.4.55%1,482,4345.77MSep 29, 2024
Perceptive Advisors Llc4.33%1,410,4385.49MSep 29, 2024
Adage Capital Partners GP L.L.C.3.46%1,127,5364.39MSep 29, 2024

Fund ownership

PEPG fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.51%492,8011.92MSep 29, 2024
iShares Russell 2000 ETF1.22%396,7791.54MOct 30, 2024
Vanguard Extended Market Index Fund0.89%289,4771.13MSep 29, 2024
Fidelity Small Cap Index Fund0.49%158,985618.45KAug 30, 2024
iShares Russell 2000 Growth ETF0.37%120,157467.41KOct 30, 2024
Fidelity Extended Market Index Fund0.29%95,295370.70KOct 30, 2024
Advertisement